-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Enzo Biochem
- The Trade: Enzo Biochem, Inc. (NYSE:ENZ) 10% owner James G Wolf bought a total of 303,000 shares at an average price of $2.47. To acquire these shares, it cost around $749.4 thousand.
- What's Happening: Enzo Biochem has been granted U.S. patent number 11,554,111 Titled "Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection."
- What Enzo Biochem Does: Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally.
Xos
- The Trade: Xos, Inc. (NASDAQ:XOS) Director George N Mattson acquired a total of 128,666 shares at an average price of $0.98. The insider spent around $126.38 thousand to buy those shares.
- What's Happening: The company's stock jumped 69% over the past month.
- What Xos Does: Xos Inc is an electric mobility company. It designs and develops fully electric battery mobility systems specifically for commercial fleets.
Check This Out: Top Real Estate Stocks That May Rally
Myomo
- The Trade: Myomo, Inc. (NYSE:MYO) CEO Paul R Gudonis acquired a total of 307,692 shares at an average price of $0.33. To acquire these shares, it cost around $100 thousand.
- What's Happening: Myomo recently priced its $6.5 million public offering at $0.325 per share.
- What Myomo Does: Myomo Inc is a medical robotics company. It develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders.
Don't forget to check out our premarket coverage here
Context Therapeutics
- The Trade: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Martin Lehr acquired a total of 6,783 shares at an average price of $0.74. The insider spent $5 thousand to buy those shares.
- What's Happening: Context Therapeutics and Lonza recently announced that the companies are collaborating to manufacture CTIM-76, Context's clinical development candidate.
- What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯週三收盤超過 600 點。當內部人士購買或出售股票時,表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以認為這是他們整體投資或交易決策的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是最近一些細價股的著名內幕交易。欲了解更多信息,請查看 本辛加的內幕交易 平台。
Enzo Biochem
恩佐生物化学
- The Trade: Enzo Biochem, Inc. (NYSE:ENZ) 10% owner James G Wolf bought a total of 303,000 shares at an average price of $2.47. To acquire these shares, it cost around $749.4 thousand.
- What's Happening: Enzo Biochem has been granted U.S. patent number 11,554,111 Titled "Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection."
- What Enzo Biochem Does: Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally.
- 貿易: 恩佐生化有限公司 紐約證券交易所代碼:ENZ)10% 的所有者詹姆斯 G 沃爾夫 買入總共 3 萬股 平均價格為 2.47 美元。要收購這些股票,其成本約為 749.4 萬美元。
- 發生了什麼事: 恩佐 Biochem 已被授予美國專利號 11,554,111,標題為「用於治療冠狀病毒感染的氨基苯胺途徑調節化合物」。
- 恩佐生化是做什麼的: 恩佐生物化學公司是一家生物科學公司。該公司向國際臨床實驗室,專業診所以及研究人員和醫生生產,開發和銷售其專有解決方案和平台。
Xos
Xos
- The Trade: Xos, Inc. (NASDAQ:XOS) Director George N Mattson acquired a total of 128,666 shares at an average price of $0.98. The insider spent around $126.38 thousand to buy those shares.
- What's Happening: The company's stock jumped 69% over the past month.
- What Xos Does: Xos Inc is an electric mobility company. It designs and develops fully electric battery mobility systems specifically for commercial fleets.
- 貿易: 克索斯公司 (納斯達克:XOS) 導演喬治 ·N· 馬特森 購入合共一百二十六股股份 平均價格為 0.98 美元。內部人士花費了大約 126.38 萬美元購買這些股票。
- 發生了什麼:該公司的股票在過去一個月上漲了 69%。
- Xos 做了什麼: Xos 公司是一家電動出行公司。它專門為商業車隊設計和開發全電動電池移動系統。
Check This Out: Top Real Estate Stocks That May Rally
看看這個: 頂級房地產股票可能會反彈
Myomo
妙雲
- The Trade: Myomo, Inc. (NYSE:MYO) CEO Paul R Gudonis acquired a total of 307,692 shares at an average price of $0.33. To acquire these shares, it cost around $100 thousand.
- What's Happening: Myomo recently priced its $6.5 million public offering at $0.325 per share.
- What Myomo Does: Myomo Inc is a medical robotics company. It develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders.
- 貿易: 妙盟股份有限公司 紐約證券交易所代碼:MYO) 首席執行官保羅 ·R 古多尼斯 購入合共 307,692 股股份 平均價格為 0.33 美元。要收購這些股票,它的成本約為 100 萬美元。
- 發生了什麼: Myomo 最近以每股 0.325 美元的價格定價為 650 萬美元的公開發行。
- 妙雲做什麼: Myomo 公司是一家醫療機器人公司。它為患有神經肌肉疾病的人開發,設計和生產肌電矯形器。
Don't forget to check out our premarket coverage here
不要忘記在這裡查看我們的售前覆蓋範圍
Context Therapeutics
上下文治療
- The Trade: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Martin Lehr acquired a total of 6,783 shares at an average price of $0.74. The insider spent $5 thousand to buy those shares.
- What's Happening: Context Therapeutics and Lonza recently announced that the companies are collaborating to manufacture CTIM-76, Context's clinical development candidate.
- What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
- 貿易: 上下文治療公司 (納斯達克:CNTX)首席執行官馬丁·勒爾 購入合共 6,783 股股份 平均價格為 0.74 美元。內幕人士花了 5 萬美元購買這些股票。
- 發生了什麼: 上下文治療和龍沙最近宣布,這些公司正在合作製造上下文的臨床開發候選人 CTIM-76。
- 什麼上下文治療: Context Theraptics Inc 是一家臨床階段的生物製藥公司,致力於改善患癌症婦女的生活。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧